AUSTIN, Texas, Feb. 18, 2016 (GLOBE NEWSWIRE) — XBiotech (NASDAQ:XBIT), developer of True Human™ therapeutic antibodies, today announced that Kalidip “KC” Choudhury, Ph.D, Vice President of Business Development, and Michael Stecher, M.D., Medical Director, will present at the 4th Annual Sachs Cancer BioPartnering & Investment Forum on February 24th at 3pm in New York, NY.
The 4th Annual Sachs Cancer BioPartnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment.
Dr. Choudhury’s and Dr. Stecher’s presentation will showcase recent corporate activities and highlight investment and partnership opportunities to this audience comprised of financial and industry insiders. Central to the presentation will be a status update on XBiotech’s lead oncology product, Xilonix™. As reported by XBiotech, Xilonix recently completed a successful Phase 3 study in advanced colorectal cancer utilizing novel objective response criteria for EMA approval. Additionally, XBiotech is conducting a separate, U.S.-directed Phase 3 study of Xilonix (XCITE) in advanced colorectal cancer.
Dr. Choudhury stated, “Having successfully completed our European Phase 3 study in a highly refractory, infirm group of patients, we are looking forward to sharing more about our remarkable cancer therapy. We’re committed to maximizing the value to our shareholders as well as the potential reach of Xilonix by examining attractive partnerships while the company advances its products toward potential commercialization in the U.S. and Europe.”
About XBiotech
XBiotech is pioneering the discovery and development of targeted antibodies based on its True Human™ technology. The company’s mission is to rethink the way antibody medicines are discovered and commercialized by advancing its robust pipeline of human antibodies for treating serious diseases such as cancer, inflammatory conditions and infectious diseases. XBiotech’s lead product, Xilonix™, is a potential breakthrough antibody therapy that is currently the subject of two pivotal clinical studies for treating patients with advanced colorectal cancer. Xilonix specifically targets and neutralizes interleukin-1 alpha (IL-1a), a molecule known to promote angiogenesis, growth and spread of tumors, as well as mediate symptoms such as metabolic dysregulation, fatigue and anxiety associated with advanced cancer. XBiotech’s True Human antibodies are cloned directly from individual donors who possess natural immunity against certain diseases. For more information, visit www.xbiotech.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements, including declarations regarding management’s beliefs and expectations, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “would,” “could,” “expects,” “plans,” “contemplate,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “intend” or “continue” or the negative of such terms or other comparable terminology, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause the actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties are subject to the disclosures set forth in the “Risk Factors” section of certain of our SEC filings. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
CONTACT: Contact: Ashley Otero XBiotech aotero@xbiotech.com 512.386.2930 Tiberend Strategic Advisors, Inc.: Joshua Drumm, Ph.D. (investors) jdrumm@tiberend.com 212.375.2664 Janine McCargo (media) jmccargo@tiberend.com 646.604.5150
